866-997-4948(US-Canada Toll Free)

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 215 Pages

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H2 2017, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 5, 8, 1, 44, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Overview 6
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics Development 7
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Therapeutics Assessment 18
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Companies Involved in Therapeutics Development 28
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Drug Profiles 44
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects 188
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Discontinued Products 194
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Product Development Milestones 195
Appendix 206

List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Aeolus Pharmaceuticals Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Angion Biomedica Corp, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Atox Bio Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by AVM Biotechnology LLC, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by BCN Biosciences LLC, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Bolder Biotechnology Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellerant Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cellphire Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Cleveland BioLabs Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by FirstString Research Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Galera Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Genzyme Corp, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by GNI Group Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Humanetics Corp, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Insys Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Meabco A/S, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Medesis Pharma SA, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Neumedicines Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Nohla Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Onconova Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Original BioMedicals Co Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by PharmaIN Corp, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Pluristem Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RDD Pharma Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RedHill Biopharma Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by RxBio Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Shuttle Pharmaceuticals LLC, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by SK Chemicals Co Ltd, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Soligenix Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Synedgen Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by TSRL Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by viDA Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Pipeline by Windtree Therapeutics Inc, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H2 2017 (Contd..1), H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H2 2017 (Contd..2), H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Dormant Projects, H2 2017 (Contd..3), H2 2017
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *